Ox­ford Vacmedix moves can­cer vac­cines for­ward with $12.5M from South Ko­rea, Chi­na

South Ko­rea and Chi­nese in­vestors have sunk a col­lec­tive $12.5 mil­lion in­to an Ox­ford Uni­ver­si­ty spin­out that promis­es a more ef­fi­cient and cheap­er way to make can­cer vac­cines.

Shisong Jiang

The fi­nanc­ing round po­ten­tial­ly opens up the Ko­re­an mar­ket for Ox­ford Vacmedix (OVM), which al­ready out-li­censed its re­com­bi­nant over­lap­ping pep­tide tech­nol­o­gy to a joint ven­ture reg­is­tered in Hong Kong. Much of the sci­ence, how­ev­er, ac­tu­al­ly takes place in Changzhou (be­tween Nan­jing and Shang­hai), where an OVM cen­ter has been con­duct­ing ear­ly-stage val­i­da­tion of the tech­nol­o­gy de­vel­oped by sci­en­tif­ic founder and CSO Shisong Jiang.

He found a way to pro­duce over­lap­ping pep­tides in a bac­te­r­i­al sys­tem, rather than syn­the­siz­ing them chem­i­cal­ly, re­sult­ing in an end­less stream of re­com­bi­nant pro­tein and the over­lap­ping pep­tides.

Jiang, who earned his med­ical de­gree in Chi­na, came to Ox­ford by way of the Lon­don School of Hy­giene and Trop­i­cal Med­i­cine and Har­vard’s Dana Far­ber Can­cer In­sti­tute, where he com­plet­ed his PhD and did post-doc work, re­spec­tive­ly. He start­ed down the road of en­tre­pre­neur­ship in 2012 and im­me­di­ate­ly looked to Chi­na for growth op­por­tu­ni­ties.

Both pri­vate in­vestors — with back­grounds in con­struc­tion/en­gi­neer­ing and ad­ver­tis­ing, re­spec­tive­ly — and the gov­ern­ment chipped in for the Changzhou fa­cil­i­ty, and have come back for this round of fi­nanc­ing.

An­tho­ny Coombs

They are joined by Can­cer ROP, a South Ko­re­an health­care in­sti­tu­tion that re­cent­ly start­ed fo­cus­ing on can­cer drugs. It is al­so close­ly as­so­ci­at­ed with one of the biggest hos­pi­tal groups in the coun­try, Ox­ford Vacmedix di­rec­tor An­tho­ny Coombs told End­points News, which can help the biotech iden­ti­fy where its can­cer vac­cines can best be used.

“We look for­ward to a pro­duc­tive and mu­tu­al­ly ben­e­fi­cial part­ner­ship with OVM es­pe­cial­ly in glob­al clin­i­cal tri­al as­pects and con­fi­dent that we can sup­port the con­tin­ued growth and de­vel­op­ment of the com­pa­ny,” said Can­cer ROP CEO Wang-Jun Lee in a state­ment.

The new funds will car­ry OVM through pre­clin­i­cal de­vel­op­ment to the be­gin­ning of Phase I tri­als in two lead pro­grams: OVM-100 is an HPV vac­cine tar­get­ing cer­vi­cal can­cer, while OVM-200 at­tacks sol­id tu­mors with an apop­to­sis in­hibitor called sur­vivin. (The PhI tri­als are ex­pect­ed to com­mence this year.) The biotech is al­so hop­ing to de­vel­op its man­u­fac­tur­ing ca­pac­i­ties from lab to pro­duc­tion scale, at which point it plans to out­source the work to a UK con­tract man­u­fac­tur­ing or­ga­ni­za­tion.

Asian mon­ey has been flow­ing around the UK.

When British Prime Min­is­ter There­sa May vis­it­ed Chi­na last month, Chi­nese in­vestors pledged $1.3 bil­lion to UK life sci­ence in­vest­ments, and Bei­jing’s Ts­ingHua Uni­ver­si­ty un­veiled a joint ear­ly-stage re­search cen­ter with Cam­bridge’s Trin­i­ty Col­lege. South Ko­rea’s largest ven­ture cap­i­tal firm, Ko­rea In­vest­ment Part­ners, backed UK syn­thet­ic bi­ol­o­gy play­er Prokar­i­um in a $10 mil­lion round an­nounced just days ago.

”(T)here’s a lot of ap­petite in Asia (…) peo­ple are very in­ter­est­ed to ac­tu­al­ly en­gage with the re­al­ly good aca­d­e­m­ic work that’s be­ing done in Ox­ford,” Coombs said.

As Nas­daq en­rolls the fi­nal batch of 2019 IPOs, how have the num­bers com­pared to past years?

IGM Biosciences’ upsized IPO haul, coming after SpringWorks’ sizable public debut, has revved up some momentum for the last rush of biotech IPOs in 2019.

With 39 new listings on the books and roughly two more months to go before winding down, Nasdaq’s head of healthcare listings Jordan Saxe sees the exchange marking 50 to 60 biopharma IPOs for the year.

“December 15 is usually the last possible day that companies will price,” he said, as companies get ready for business talks at the annual JP Morgan Healthcare Conference in January.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 59,900+ biopharma pros reading Endpoints daily — and it's free.

A fa­vorite in Alex­ion’s C-suite is leav­ing, and some mighty sur­prised an­a­lysts aren’t the least bit hap­py about it

Analysts hate to lose a biotech CFO they’ve come to trust and admire — especially if they’re being blindsided by a surprise exit.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 59,900+ biopharma pros reading Endpoints daily — and it's free.

David Grainger [file photo]

'Dis­con­nect the bas­tard­s' — one biotech's plan to break can­cer cell­s' uni­fied de­fens­es

Chemotherapy and radiotherapy are the current gladiators of cancer treatment, but they come with well-known limitations and side-effects. The emergence of immunotherapy — a ferocious new titan in oncologist’s toolbox — takes the brakes off the immune system to kill cancer cells with remarkable success in some cases, but the approach is not always effective. What makes certain forms of cancer so resilient? Scientists may have finally pieced together a tantalizing piece of the puzzle, and a new biotech is banking on a new approach to fill the gap.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 59,900+ biopharma pros reading Endpoints daily — and it's free.

While No­var­tis ban­ish­es Zol­gens­ma scan­dal scars — Bio­gen goes on a Spin­raza 'of­fen­sive'

While Novartis painstakingly works to mop up the stench of the data manipulation scandal associated with its expensive gene therapy for spinal muscular atrophy (SMA) Zolgensma— rival Biogen is attempting to expand the use of its SMA therapy, Spinraza. 

The US drugmaker $BIIB secured US approval for Spinraza for use in the often fatal genetic disease in 2016. The approval covered a broad range of patients with infantile-onset (most likely to develop Type 1) SMA. 

Jason Kelly. Mike Blake/Reuters via Adobe

Eye­ing big ther­a­peu­tic push, Gink­go bags $290M to build a cell pro­gram­ming em­pire

Ginkgo Bioworks is on a roll. Days after publicizing a plan to nurture new startups via partnerships with accelerators Y Combinator and Petri, the Boston biotech says it has raised another $290 million for its cell programming platform to reach further and wider.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 59,900+ biopharma pros reading Endpoints daily — and it's free.

UP­DAT­ED: Speak­er Nan­cy Pelosi to un­veil bill for fed­er­al­ly ne­go­ti­at­ed drug prices

After months of buzz from both sides of the aisle, Speaker Nancy Pelosi will today introduce her plan to allow the federal government to negotiate prices for 250 prescription drugs, setting up a showdown with a pharmaceutical industry working overtime to prevent it.

The need to limit drug prices is a rare point of agreement between President Trump and Democrats, although the president has yet to comment on the proposal and will likely face pressure to back a more conservative option or no bill at all. Republican Senator Chuck Grassley is reportedly lobbying his fellow party members on a more modest proposal he negotiated with Democratic Senator Ron Wyden in July.

Jeff Kindler's Cen­trex­ion re­news bid to make pub­lic de­but

Jeffrey Kindler’s plan to take his biotech — which is developing a slate of non-opioid painkillers — public, is back on.

The Boston based company, led by former Pfizer $PFE chief Kindler, originally contemplated a $70 million to $80 million IPO last year— but eventually postponed that strategy. On Wednesday, the company revived its bid to make a public debut in a filing with the SEC — although no pricing details were disclosed.

Zachary Hornby. Boundless

'A fourth rev­o­lu­tion in can­cer ther­a­pies': ARCH-backed Bound­less Bio flash­es big check, makes big­ger promis­es in de­but

It was the cellular equivalent of opening your car door and finding an active, roaring engine in the driver seat.

Scientists learned strands of DNA could occasionally appear outside of its traditional home in the nucleus in the 1970s, when they appeared as little, innocuous circles on microscopes; inexplicable but apparently innate. But not until UC San Diego’s Paul Mischel published his first study in Science in 2014 did researchers realize these circles were not only active but potentially overactive and driving some cancer tumors’ superhuman growth.

Scott Gottlieb, AP Images

Scott Got­tlieb is once again join­ing a team that en­joyed good times at the FDA un­der his high-en­er­gy stint at the helm

Right after jumping on Michael Milken’s FasterCures board on Monday, the newly departed FDA commissioner is back today with news about another life sciences board post that gives him a ringside chair to cheer on a lead player in the real-world evidence movement — one with very close ties to the FDA.

Aetion is reporting this morning that Gottlieb is joining their board, a group that includes Mohamad Makhzoumi, a general partner at New Enterprise Associates, where Gottlieb returned after stepping out of his role at the FDA 2 years after he started.

Gottlieb — one of the best connected execs in biopharma — knows this company well. As head of FDA he championed the use of real-world evidence to help guide drug developers and the agency in gaining greater efficiencies, which helped set up Aetion as a high-profile player in the game.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 59,900+ biopharma pros reading Endpoints daily — and it's free.